Amgen (AMGN) 174.16 $AMGN Amgen (AMGN) Breaks Through

New Post Public Reply Private Reply Replies (0) Message Board

Aug 2, 2016 at 6:13 AM

Amgen (AMGN) 174.16 $AMGN

Amgen (AMGN) Breaks Through Resistance at $172.68
Comtex SmarTrend(R) - Mon Aug 01, 8:46AM CDT
Amgen (NASDAQ:AMGN) has opened bullishly above the pivot of $171.61 today and has reached the first level of resistance at $172.68. Investors may be interested in a cross of the next upside pivot targets of $173.34 and $175.07.
AMGN: 174.16 (+2.13)

Top 7 Research Reports for July 29, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 29, 12:44PM CDT
Top 7 Research Reports for July 29, 2016
MDLZ: 43.48 (-0.50), JPM: 63.80 (-0.17), TMO: 159.56 (+0.72), AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), TM: 111.23 (-0.37), ORCL: 41.15 (+0.11)

UCB (UCBJF) Posts 1H16 Results, Reaffirms 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:15AM CDT
UCB (UCBJF) reported results for the first half of 2016.
BIIB: 301.83 (+11.90), AMGN: 174.16 (+2.13), NKTR: 17.76 (+0.47)

Company News for July 29, 2016
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:10AM CDT
Companies In The News are: CELG,MA,HOG,AMGN
HOG: 51.66 (-1.26), AMGN: 174.16 (+2.13), MA: 95.07 (-0.17), CELG: 114.69 (+2.50)

Next Support Level for Amgen (AMGN) is $166.09
Comtex SmarTrend(R) - Thu Jul 28, 9:12AM CDT
Amgen (NASDAQ:AMGN) has opened bearishly below the pivot of $169.74 today and has reached the first level of support at $168.38. Investors may be interested in a cross of the next downside pivot targets of $166.09 and $162.44.
AMGN: 174.16 (+2.13)

The Zacks Analyst Blog Highlights: Facebook, Amgen, Whole Foods and Groupon
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Facebook, Amgen, Whole Foods and Groupon
WFM: 30.41 (-0.07), FB: 124.31 (+0.37), AMGN: 174.16 (+2.13), GRPN: 4.99 (+0.17)

The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 301.83 (+11.90), GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Amgen (AMGN) Tops Q2 Earnings & Revenues, Raises View
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 7:02AM CDT
Amgen (AMGN) once again delivered a "beat and raise" quarter with growth products accounting for more than 50% of product sales.
BIIB: 301.83 (+11.90), INVA: 13.04 (+0.17), AMGN: 174.16 (+2.13), FMS: 45.65 (unch)

2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), MRK: 58.66 (unch), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71)

Facebook (FB) Owns Q2 Earnings on Huge Beat, Plus GRPN, GPRO and More
Mark Vickery - Zacks Investment Research - Wed Jul 27, 4:47PM CDT
Facebook (FB) has been priced to near-perfection, and in Q2 2016, it has indeed delivered. And Groupon shoots to the moon after hours.
WFM: 30.41 (-0.07), GPRO: 12.94 (+0.30), FB: 124.31 (+0.37), AMGN: 174.16 (+2.13), GRPN: 4.99 (+0.17)

Amgen Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Jul 27, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2016. Key results include:
AMGN: 174.16 (+2.13)

Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 301.83 (+11.90), VRTX: 98.20 (+1.20), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), CELG: 114.69 (+2.50)

Covered Call reports for Chipotle Mexican Grill, Starwood Hotels & Resorts Worldwide, JetBlue, Amgen and Whole Foods Market include trade ideas that offer returns of 20% or more!
PR Newswire - Wed Jul 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMGN, CMG, HOT, JBLU, and WFM.
WFM: 30.41 (-0.07), CMG: 414.08 (-9.91), AMGN: 174.16 (+2.13), JBLU: 18.20 (-0.13), HOT: 77.71 (-0.35)

5 Drug Stocks' Earnings on Jul 27: AMGN, VRTX & More
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 9:36AM CDT
How will drug stocks like AMGN, GSK, VRTX and others, scheduled to report on Jul 27, fare this earnings season?
BIIB: 301.83 (+11.90), JNJ: 125.40 (+0.17), VRTX: 98.20 (+1.20), MDCO: 39.03 (-0.08), AMGN: 174.16 (+2.13), GSK: 45.25 (+0.18), ANIK: 50.64 (+0.72)

AbbVie (ABBV) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 9:11AM CDT
Will Imbruvica and Humira help AbbVie (ABBV) deliver a positive earnings surprise in Q2?
JNJ: 125.40 (+0.17), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13), ABBV: 66.94 (+0.71), BMY: 76.19 (+1.38)

Alexion (ALXN) Q2 Earnings: Stock Likely to Disappoint
Zacks Equity Research - Zacks Investment Research - Tue Jul 26, 8:43AM CDT
Alexion Pharmaceuticals (ALXN), which is set to report second-quarter 2016 results on Jul 28, had delivered a negative earnings surprise of 4.40% last quarter.
UTHR: 125.08 (+4.07), ALXN: 133.50 (+4.90), AMGN: 174.16 (+2.13), BMY: 76.19 (+1.38)

Merck (MRK) Q2 Earnings: Will the Stock Pull a Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 6:24AM CDT
Merck (MRK) had posted a positive earnings surprise in Q1. Will the stock deliver a positive surprise again this quarter?
BMRN: 100.25 (+0.83), MRK: 58.66 (unch), ICPT: 169.72 (-3.31), AMGN: 174.16 (+2.13)

ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 100.25 (+0.83), INCY: 90.00 (-0.21), AMGN: 174.16 (+2.13), ARIA: 9.71 (+0.20)

Biotech Earnings Battle: Gilead (GILD) vs. Amgen (AMGN)
Eric Dutram - Zacks Investment Research - Mon Jul 25, 2:49PM CDT
Amgen and Gilead Sciences are both reporting earnings this week. Which company is the better bet right now?
GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13)

Valeant's (VRX) Brodalumab BLA Up for Review in the U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:49PM CDT
Valeant Pharmaceuticals International, Inc.'s (VRX) Biologic License Application (BLA) for brodalumab is up for review by an FDA panel.
VRX: 20.89 (-1.41), AZN: 33.84 (-0.30), AMGN: 174.16 (+2.13), BMY: 76.19 (+1.38)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Revamping Children's Radiotherapy: Leo Cancer Care's Vision

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Accuray, Samsung Push Boundaries with Imaging Deal

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

AI Memory Growth Pushes Limits at GMIF2026 Summit

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

DKS Facing Class Action Over Stock Slump Allegations

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Salveo Home Care Faces Class Action Over Labor Violations

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Melrose Fire Station Reaches Steel Topping Milestone

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...